BELLUS Health ^{Priced, Nasdaq: BLU}

We are a clinical stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic cough and other hypersensitization disorders. Our product candidate, BLU-5937, is a twice daily oral small molecule, specifically designed to be a highly selective inhibitor of the P2X3 receptor, a clinically validated target linked to hypersensitivity. We are developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. These hypersensitization-related disorders, which share a common pathophysiology that is mediated through the P2X3 receptor, represent areas of significant unmet medical need and potentially large market opportunities. We are led by a team of executives with extensive experience in drug development, having held leadership roles at numerous biopharmaceutical companies, including, but not limited to, GlaxoSmithKline, Astra Zeneca and Biochem Pharma.